A new combination pill to lower LDL cholesterol in adults who haven’t taken cholesterol medicine before

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 trial compares the effects and safety of a fixed-dose combination of laroprovstat with rosuvastatin against rosuvastatin alone, laroprovstat alone, and placebo in adults with high cholesterol who have not used lipid-lowering therapy recently. Participants are 18 or older and have no history of ASCVD and low 10-year ASCVD risk. The study measures changes in LDL-C and evaluates safety and tolerability. Locations include sites in Dothan, AL; Chandler, AZ; and Phoenix, AZ, sponsored by AstraZeneca. Eligible participants must not have statin intolerance and must have controlled comorbidities to join.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must be ≥ 18 years of age
* Participants with no clinical history of atherosclerotic cardiovascular disease (ASCVD) and a 10-year ASCVD risk estimated as low
* Participants who have not received any LLT in the 3 months prior to screening

Exclusion Criteria:

* Asian origin.
* Statin intolerance
* Uncontrolled severe hypertension
* Uncontrolled type 2 diabetes mellitus
* Inadequately treated hypothyroidism

Where it's running

• Research Site
  Colorado Springs, Colorado, United States Recruiting
• Research Site
  Lakeland, Florida, United States Recruiting
• Research Site
  Conyers, Georgia, United States Recruiting
• Research Site
  Hinesville, Georgia, United States Recruiting
• Research Site
  Lexington, Kentucky, United States Recruiting
• Research Site
  Millville, New Jersey, United States Recruiting

+102 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: +18772409479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Linking social care with healthcare to help manage chronic diseases

  This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.

  Recruiting at 2 sites University of Arizona · Tucson, Arizona and 1 other locations · NCT07799961

• Fixed-dose combination of laroprovstat/rosuvastatin vs rosuvastatin alone for high cholesterol

  This study tests whether a fixed-dose combo pill of laroprovstat and rosuvastatin lowers LDL cholesterol better than rosuvastatin alone in adults with high cholesterol who have or are at risk for cardiovascular disease.

  Recruiting at 16 sites Phase 3 AstraZeneca · Sun City West, Arizona and 44 other locations · NCT07619118

• Obicetrapib vs. bempedoic acid for high-risk high cholesterol patients

  This phase 3 study tests whether obicetrapib can lower LDL-C more than bempedoic acid in adults with primary non-familial hypercholesterolemia or mixed dyslipidemia who still have high LDL-C despite maximum tolerated therapy.

  Recruiting Phase 3 A. Menarini International Licensing S.A. · Stockton-on-Tees · NCT07614958

• Combination therapy with QCZ484 and Inclisiran for hypertension with high cholesterol

  This study tests whether the drug QCZ484, alone or with Inclisiran, lowers cholesterol and helps blood pressure in adults with hypertension and high cholesterol.

  Recruiting at 29 sites Phase 2 Novartis · Foley, Alabama and 28 other locations · NCT07610278

• CTX310 for refractory high triglycerides or LDL cholesterol

  This trial will test whether a single IV dose of CTX310 is safe and tolerated in adults whose high triglycerides or LDL cholesterol have not responded to available treatments.

  Recruiting at 16 sites Phase 1 CRISPR Therapeutics · Hialeah, Florida and 16 other locations · NCT07491172

• Adherence, persistence, and real-life effectiveness of alirocumab 300 mg for people with high cholesterol in Italy

  This project will test whether alirocumab 300 mg helps people with high cholesterol in Italy stick with their treatment and lower their cholesterol when used in routine care.

  Recruiting Federico II University · Naples, Napoli · NCT07375225

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.